Company intelligence / Profile preview

Astek Diagnostics

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Astek Diagnostics is developing a rapid point-of-care diagnostic platform (JIDDU) that can determine, within one hour, whether a patient has a urinary tract infection (UTI) and which antibiotics are likely to be effective for treatment. This technology aims to significantly reduce complications, unnecessary antibiotic use, and healthcare costs associated with misdiagnosed and mistreated UTIs, which account for 25% of sepsis cases in the US. The company has achieved notable initial results in clinical validation and is targeting a market entry in 2025[1][3][5].

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic platform
Industry: Molecular Diagnostics

Partnerships

University of Maryland Medical CenterMedStar Health

Beyond the preview

Go deeper on Astek Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astek Diagnostics.

Explore the full profile